Solifenacin succinate is an antimuscarinic medication primarily used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It works by blocking muscarinic receptors in the bladder, reducing involuntary bladder contractions and improving urinary control. This helps alleviate symptoms such as frequent urination, sudden urges to urinate, and urinary incontinence, making it particularly beneficial for individuals experiencing bladder dysfunction due to neurological conditions. By relaxing the detrusor muscle of the bladder, solifenacin helps increase bladder storage capacity and reduces the urgency and frequency of urination, thereby improving overall bladder function and patient comfort.

Solifenacin is generally well-tolerated, but it may cause side effects such as dry mouth, constipation, blurred vision, and dizziness, due to its anticholinergic properties. In some cases, it can lead to urinary retention, especially in patients with pre-existing bladder emptying issues. Long-term use requires careful monitoring, particularly in elderly patients, as antimuscarinic medications may impact cognitive function. Despite these potential side effects, solifenacin remains a widely used and effective treatment for individuals with overactive bladder and neurogenic detrusor overactivity, helping them achieve better bladder control, reduced urgency, and an improved quality of life.